A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

Keyphrases

• Accruals 20%
• Acute Myeloid Leukemia 100%
• Adverse Events 20%
• Anemia 20%
• AZD2171 100%
• Cediranib 100%
• Complete Remission 20%
• Dehydration 20%
• Diarrhea 20%
• Disease Response 20%
• Dyspnea 20%
• Flt-1 20%
• Hematologic Improvement 20%
• High-risk Myelodysplastic Syndrome 100%
• Intensive Care Medicine 20%
• Leukemia Risk 100%
• Myelodysplastic Syndrome 60%
• Nausea 20%
• Neutropenia 20%
• Novel Therapies 20%
• Partial Remission 20%
• Phase II Study 100%
• Receptor Tyrosine Kinase Inhibitor 20%
• Stopping Rule 20%
• Therapy Options 20%
• Thrombocytopenia 20%
• Treatment Needs 20%
• Vascular Endothelial Growth Factor Receptor (VEGFR) 40%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Adverse Event 20%
• Anemia 20%
• Cediranib 100%
• Diarrhea 20%
• Diseases 20%
• Dyspnea 20%
• Myelodysplastic Syndrome 100%
• Nausea 20%
• Neutropenia 20%
• Protein Tyrosine Kinase 20%
• Protein Tyrosine Kinase Inhibitor 20%
• Remission 40%
• Thrombocytopenia 20%
• Vasculotropin Receptor 40%